Anti‐CTLA‐4: Tremelimumab (75 mg, per 4 weeks for 4 doses) was administered intravenously.Anti‐PD‐L1: Durvalumab (1500 mg, per 4 weeks) was administered intravenously.Ablation: Minimally invasive surgical microwave ablation (MIS‐MWA) of the pancreatic tumor was performed two weeks after the first dose of Durvalumab and Tremelimumab.Chemotherapy: Systemic gemcitabine (1000 mg /m2) was started 6 weeks after MIS‐MWA and given once a week for 3 weeks, followed by a week of rest. Here, CTLA4 is linked to pancreatic neoplasm.